License and Collaboration Agreements (Tables)

12 Months Ended

Dec. 31, 2014

Organization, Consolidation and Presentation of Financial Statements [Abstract]

License, Collaboration and Other Revenue

In accordance with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands):

		Year Ended December 31,
Partner	Agreement	2014		2013		2012
AstraZeneca AB	MOVANTIKTM (NKTR-118) and MOVANTIKTM fixed-dose combination program (NKTR-119)	$	105,001	$	25,016	$	59
Roche	PEGASYS® and MIRCERA®		12,845		18,382		7,146
Baxter Healthcare	BAX 855 (Hemophilia)		10,258		1,702		6,238
Amgen, Inc.	Neulasta®		5,000		5,035		5,000
Bayer Healthcare LLC	BAY41-6551 (Amikacin Inhale)		4,717		15,293		2,971
Affymax, Inc.	OMONTYS®		—		7,149		2,829
Other			15,468		8,295		5,884
License, collaboration and other revenue		$	153,289	$	80,872	$	30,127